http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Supeficial cryotherapy on the eyebrow alopecia areata: a prospective, split-face comparative study
( Sung Jay Choe ),( Won Soo Lee ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.2
Background: Numerous treatment modalities are available in treatment of alopecia areata(AA) of eyebrow. However, due to the anatomical proximity of the eyebrows to the eyes, safety issues and side-effects should always be taken into consideration when choosing the treatment modality. Superficial cryotherapy has been reported to be a therapeutically efficacious and safe for AA in several studies. Objectives: This study was designed to examine theefficacy and safety of superficial cryotherapy on the eyebrow AA patients. Methods: A total of 16 patients were applied with superficial cryotherapy on the right eyebrow for every other weeks. No specific treatment was performed on the left side as a control. The degree of the eyebrow recovery was compared in 10 patients who continued superficial cryotherapy on their right eyebrow for more than 6 times(3 months). The efficacy was evaluated by total hair counts, hair caliber and photographic assessment by investigators. Results: The total hair counts and hair caliber from the baseline after treatment increased at both sides. No statistically significant difference was observed in the rate of changes of total hair counts between right and left side. However, the rate of changes of hair caliber on the right side showed statistically significant difference when compared to that of the left side. Conclusion: This study showed that superficial cryotherapy can be an effective, safe and supportive treatment modality for the eyebrow AA patients.
Successful treatment of Darier`s disease with minocycline
( Sung Jay Choe ),( Hee Chul Chung ),( Won Soo Lee ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.1
Darier’s disease is a well-known skin disorder with familial history and autosomal dominant inheritance pattern. There are many types of treatments, but most of them are often unsuccessful. A 24-year-old female patient presented with a 3-month history of skin lesions on the neck and face. After informed consent was provided, a skin biopsy was performed from the lesional skin. Before receiving the pathologic report, treatment with minocycline 50 mg daily was administered. After 2 weeks, the histological examination revealed typical features of Darier’s disease. Two weeks after beginning treatment, her skin lesions were slightly improved, prompting continuation of the treatment. A total of 6 weeks after starting minocycline treatment, most of the lesions were substantially resolved without any complications. Minocycline is a broad-spectrum tetracycline known to have various pharmacological effects. The pharmacological actions of minocycline influence the sphingomyelinase /ceramide pathway. These actions of minocycline on the sphingolipid pathway may be involved in the therapeutic effect on SERCA2-controlled Ca2+-dependent keratinocyte adhesion and differentiation seen in Darier’s disease. In addition to, minocycline also block the NF-kappa B nuclear translocation and cell apoptosis via suppression of TNF-alpha and pro-inflammatory cytokines. Here we report a case of Darier’s disease that was successfully treated with oral minocycline
( Sung Jay Choe ),( Solam Lee ),( Jaewoong Choi ),( Won-soo Lee ) 대한피부과학회 2017 Annals of Dermatology Vol.29 No.3
Background: A variety of agents have been used to treat female pattern hair loss (FPHL), including topical minoxidil, topical 17α-estradiol, oral anti-androgen agents, and mineral supplements. Compared with these single agent regimens, combination therapies could be a better therapeutic option in expectation of superior treatment outcome. Objective: This study was designed to determine the efficacy of a combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil in Korean patients with FPHL. Methods: Therapeutic efficacy was evaluated in 34 women who applied topical 0.025% 17α-estradiol and 3% minoxidil once daily for more than 6 months. Phototrichogram analysis was performed before and after therapy. The efficacy was evaluated with respect to total hair count, hair caliber (as assessed by phototrichogram analysis), and photographic assessment. Results: Total hair count and hair caliber both increased from baseline to 6 months in patients treated with the combination therapy of topical 0.025% 17α-estradiol and 3% minoxidil (p<0.001). Photographic assessment also revealed significant disease improvement, thus supporting the therapeutic efficacy. Conclusion: A combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil can be tried as an effective treatment for FPHL. (Ann Dermatol 29(3) 276∼282, 2017)
( Sung Jay Choe ),( Won Soo Lee ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.2
Background: Currently, variety of agents for the treat of female pattern hair loss (FPHL) have been used, including topical minoxidil, topical 17メ-estradiol, oral anti-androgen agents and mineral supplements. Clinically, compared to the single agent regimen, combination therapy can be a therapeutic option in expectation of superior treatment outcomeObjectives: To objectively clarify the efficacy of the combination therapy of topical 0.025% 17メ-estradiol and 3% minoxidil in Korean FPHL patients. Methods: Therapeutic efficacy was evaluated in 34 women who applied topical 0.025% 17メ-estradiol and 3% minoxidil once daily for more than 6months and performed phototrichogram before and after therapy. The efficacy was evaluated by total hair counts, hair caliber using photorichogram and photographic assessment by investigators. Results: Total Hair counts and calibers were increased from baseline to 6 months, after combination therapy of topical 0.025% 17メ-estradiol and 3% minoxidil in treated patients (p<0.001). Therapeutic efficacy was supported by the photographic assessment of investigator, which showed significant improvement of the disease. Conclusion: This study showed that combination therapy of topical 0.025% 17メ-estradiol and 3% minoxidil can be tried as an effective treatment for FPHL
( Sung Jay Choe ),( Solam Lee ),( Chung Hyeok Lee ),( Hanil Lee ),( Won-soo Lee ) 대한피부과학회 2017 대한피부과학회 학술발표대회집 Vol.69 No.2
Background: Alopecia areata (AA) could manifest various patterns and degree, some of which are known to be associated with prognosis of disease. There are several classifications in AA, however they reflected the various prognostic factors insufficiently. Objectives: We aimed to establish a classification that reflects the prognostic factors affecting the treatment response. Methods: 94 AA patients were enrolled. We assessed correlation between treatment response and disease-related factors, including pattern and extent of scalp lesion, and presence of lesions on the body hair using multivariate logistic regression. In patients with extrascalp lesion, we assessed the correlation between treatment response and affected site and extent of extrascalp lesions separately. Results: There was a poorer response to scalp involvement with increasing extent. Furthermore, there was a significant difference in treatment response according to the pattern of scalp lesion. Besides, in patients with lesions on the extrascalp hair, there was a tendency to show worse results when involved wider areas and more sites of body hair lesions. Conclusion: We applied these results and developed a new classification based on combination of the pattern and extent of scalp hair lesion and the affected body hair site and extent. It is a new systematic, and evidence-based classification that reflects disease-associated prognostic factors.
( Sung Jay Choe ),( Solam Lee ),( Long Quan Pi ),( Dong In Keum ),( Chung Hyeok Lee ),( Beom Jun Kim ),( Won-soo Lee ) 대한피부과학회 2017 대한피부과학회 학술발표대회집 Vol.69 No.2
Background: Contact immunotherapy with diphenylcyclopropenone (DPCP) is presently considered the treatment of choice for patients with extensive alopecia areata (AA). However, the major issue with contact immunotherapy is that it causes various adverse effects (AEs) that contribute to patient discontinuation of treatment. Objectives: We investigated whether a modified DPCP treatment protocol initiated with 0.01% DPCP after sensitization with 0.1% DPCP is effective in patients with AA and results in fewer AEs. Methods: All patients were sensitized with 0.1% DPCP and began treatment with 0.01% DPCP. Thereafter, the DPCP concentration was slowly increased according to the patient’s treatment response and AEs. The relationships between treatment response and disease- and treatment-associated factors were evaluated. Results: Of the 159 patients, 46 (28.9%) showed a complete response and 59 showed a partial response (37.1%). No patients showed any AEs after the sensitization. During the challenge, 61 (38.4%) had no AEs and 50 (31.4%) had mild itching that did not require specific treatment. There was no association between treatment response and AEs. Conclusion: The use of this modified DPCP treatment protocol with subclinical sensitization could induce the favorable therapeutic response and result in fewer AEs.
Aplasia cutis congenita associated with goltz syndrome
( Sung Jay Choe ),( Solam Lee ),( Hanil Lee ),( Sung Ku Ahn ) 대한피부과학회 2016 대한피부과학회 학술발표대회집 Vol.68 No.1
A 19-year-old female presented to the outpatient department for skin defect of scalp, right leg and trunk since birth. She is the daughter of healthy unrelated parents, without any familial history of genetic diseases. Cutaneous examination revealed multiple various sized well-demarcated atrophied plaques with fat herniation and telangiectasia along the lines of Blaschko on the right lower leg. She had limb deformities in the form of syndactyly in right feet and the scalp lesion appeared as an atrophic, membranous, fibrotic alopecic scar. A biopsy of a reticulated patch of the calf revealed attenuation of dermal collagen fibers with partial loss of dermal collagen. The diagnosis of Goltz syndrome with aplasia cutis congenita was made on the basis of physical and histologic findings of the patient. Goltz syndrome, caused by mutations in PORCN, in an x-liked ectodermal dysplasia which is also known as focal dermal hypoplasia. The severity of the phenotype correlates with the level of X-chromosome inactivation. Therefore, there is great variability in physical findings, as was also observed in our case. Goltz syndrome is quite rare and some of the Goltz syndrome patients reported aplasia cutis-like areas on the skin at birth, which healed with stellate or hypertrophic scarring and associated reactive pigmentation in about 30% of the patients. Therefore, we herein report the case of Goltz syndrome with aplasia cutis congenita.